In addition, we aimed to analyze the effect of KRX-104130 on the low-density lipoprotein receptor (LDLR) gene [27,28], which affects cholesterol reduction, using a transcriptome-based drug repositioning approach [15] and to show presence of any protective effects in a mouse model of nonalcoholic steatohepatitis (NASH). This evidence concerns the gene VLDLR and metabolic dysfunction-associated steatohepatitis.